Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion

摘要: We have measured the free and peptide-bound type I collagen cross-link excretions in normal women patients with metabolic bone disease using HPLC technique immunoassays recognizing specifically or forms of pyridinoline (Pyr). After menopause, deoxypyridinoline (free D-Pyr) excretion by without urine hydrolysis expressed as a fraction total was lower than premenopausal (45 ± 15% vs. 59 12%, p > 0.005), whereas Pyr not changed. In pre- postmenopausal (n = 43), D-Pyr negatively correlated turnover rate assessed urinary (r –0.64, 0.001). variety diseases characterized increased (osteoporosis, Paget's disease, hyperthyroidism), fractions were significantly controls (p 0.001 for all diseases). 3 days intravenous (iv) treatment bisphosphonate pamidronate osteoporosis, cross-linked peptides high performance liquid chromatography (HPLC) enzyme-linked immunoassay (ELISA) (NTX CrossLaps) markedly decreased (–52% –85% NTX, –71% –93% CrossLaps™ respectively). The cross-links to lesser extent after (–25% –25% Pyr, –37% –45% and, surprisingly, either an ELISA specific unchanged treatment. contrast therapy, estrogen only but also that reduced about 30–40%. different effects therapy on confirmed gel filtration Sephadex G 25 before conclusion, we shown could result larger increase over cross-links. Bisphosphonate significant change contrasting decrease both therapy. These data suggest these two antiresorptive therapies may affect differently pattern degradation, intriguing possibility should be further investigated vitro.